
    
      For NSCLC patients with synchronous oligometastases, first line chemotherapy or targeted
      therapy concurrent with non-salvage radiotherapy on metastatic or primary thoracic tumor
      contributed a longer progression-free survival than chemotherapy or targeted therapy alone.
    
  